Literature DB >> 32560707

Screening for low testosterone is needed for early identification and treatment of men at high risk of mortality from Covid-19.

Simon Peter Rowland1, Elizabeth O'Brien Bergin2.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 32560707      PMCID: PMC7303930          DOI: 10.1186/s13054-020-03086-z

Source DB:  PubMed          Journal:  Crit Care        ISSN: 1364-8535            Impact factor:   9.097


× No keyword cloud information.
A repeated observation that disease severity and mortality rate of Covid-19 is significantly higher in male rather than female sufferers [1] has led researchers to investigate the role of sex hormones in disease progression. Recent reports of case series from China [2], Germany [3] and Italy [4] have highlighted strong associations between serum testosterone levels, inflammatory cytokines, disease progression and clinical outcomes in male Covid-19 patients, independent of patient age and comorbidities. In a cohort of 31 Italian male hospital inpatients, a significant stepwise decline in calculated free (cFT) and total testosterone (TT) levels was strongly correlated with need for escalation of care from general ward based to specialist respiratory and intensive care [4]. There was significant negative correlation between both total and free testosterone with inflammatory markers such as neutrophil count, LDH and PCT, CRP and ferritin and a positive correlation with lymphocyte count. The probability of being transferred to the ICU or dying below and above a TT level of 5 nmol/L was 14.18% [8.89–17.03] vs 0.60% [0.12–3.32] (p < 0.0001) and 12.40% [6.77–16.43] vs 0.39% [0.07–2.26] (p < 0.0001) respectively. Similar observations were made in a cohort of 45 German patients with approximately 70% having low testosterone on admission to ICU with 7 of the 9 subsequent mortalities having significantly reduced TT levels [3]. Low testosterone levels in men admitted to hospital with acute illness have previously been described in published data and have similarly been directly associated with risk of admission to intensive care and severity of disease, as measured by likelihood of development of ARDS, length of ICU stay and mortality [5]. Expert commentators have however put forward hypothesise for disease-specific processes to suggest a potentially causative effect of low testosterone on adverse clinical outcomes in Covid-19. One theory is that low testosterone levels could theoretically be detrimental because of the role of testosterone in inducing the angiotensin-converting enzyme 2 (ACE2) expression, which is an important lung protective enzyme. Further research is needed to define the cause and effect relationship between testosterone and severe acute illness from Covid-19; however, the importance of low testosterone as a prognostic marker of severe disease is clear and as yet underrecognised in men with Covid-19. We call for wider screening of testosterone levels in men admitted to hospital with symptoms of Covid-19 as a strategy to identify those at highest risk of severe disease leading to ICU admission and mortality.
  3 in total

1.  Hypogonadism in aged hospitalized male patients: prevalence and clinical outcome.

Authors:  P Iglesias; F Prado; M C Macías; M T Guerrero; A Muñoz; E Ridruejo; P Tajada; C García-Arévalo; J J Díez
Journal:  J Endocrinol Invest       Date:  2014-01-09       Impact factor: 4.256

2.  Low testosterone levels predict clinical adverse outcomes in SARS-CoV-2 pneumonia patients.

Authors:  Giulia Rastrelli; Vincenza Di Stasi; Francesco Inglese; Massimiliano Beccaria; Martina Garuti; Domenica Di Costanzo; Fabio Spreafico; Graziana Francesca Greco; Giulia Cervi; Antonietta Pecoriello; Angela Magini; Tommaso Todisco; Sarah Cipriani; Elisa Maseroli; Giovanni Corona; Andrea Salonia; Andrea Lenzi; Mario Maggi; Giuseppe De Donno; Linda Vignozzi
Journal:  Andrology       Date:  2020-06-03       Impact factor: 4.456

3.  Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study.

Authors:  Fei Zhou; Ting Yu; Ronghui Du; Guohui Fan; Ying Liu; Zhibo Liu; Jie Xiang; Yeming Wang; Bin Song; Xiaoying Gu; Lulu Guan; Yuan Wei; Hui Li; Xudong Wu; Jiuyang Xu; Shengjin Tu; Yi Zhang; Hua Chen; Bin Cao
Journal:  Lancet       Date:  2020-03-11       Impact factor: 79.321

  3 in total
  11 in total

Review 1.  Androgens in SARS-CoV-2 coronavirus infections.

Authors:  L Stárka; M Dušková
Journal:  Physiol Res       Date:  2021-12-16       Impact factor: 1.881

2.  Testosterone in males with COVID-19: A 7-month cohort study.

Authors:  Andrea Salonia; Marina Pontillo; Paolo Capogrosso; Silvia Gregori; Cristina Carenzi; Anna Maria Ferrara; Isaline Rowe; Luca Boeri; Alessandro Larcher; Giuseppe A Ramirez; Cristina Tresoldi; Massimo Locatelli; Giulio Cavalli; Lorenzo Dagna; Antonella Castagna; Alberto Zangrillo; Moreno Tresoldi; Giovanni Landoni; Patrizia Rovere-Querini; Fabio Ciceri; Francesco Montorsi
Journal:  Andrology       Date:  2021-08-31       Impact factor: 4.456

3.  Role of testosterone in COVID-19 patients - A double-edged sword?

Authors:  Aneela N Hussain; Fazal Hussain; Shahrukh K Hashmi
Journal:  Med Hypotheses       Date:  2020-09-17       Impact factor: 1.538

Review 4.  Testosterone target therapy: focus on immune response, controversies and clinical implications in patients with COVID-19 infection.

Authors:  Stefano Salciccia; Francesco Del Giudice; Michael L Eisenberg; Claudio M Mastroianni; Ettore De Berardinis; Gian Piero Ricciuti; Pietro Viscuso; Antonella Zingaropoli; Patrizia Pasculli; Maria Rosa Ciardi; Alessandro Sciarra; Martina Maggi
Journal:  Ther Adv Endocrinol Metab       Date:  2021-04-22       Impact factor: 3.565

Review 5.  Sex-based differences in severity and mortality in COVID-19.

Authors:  Mustafa Alwani; Aksam Yassin; Raed M Al-Zoubi; Omar M Aboumarzouk; Joanne Nettleship; Daniel Kelly; Ahmad R Al-Qudimat; Ridwan Shabsigh
Journal:  Rev Med Virol       Date:  2021-03-01       Impact factor: 11.043

6.  Association Between Sex Hormone Levels and Clinical Outcomes in Patients With COVID-19 Admitted to Hospital: An Observational, Retrospective, Cohort Study.

Authors:  Anna Beltrame; Pedro Salguero; Emanuela Rossi; Ana Conesa; Lucia Moro; Laura Rachele Bettini; Eleonora Rizzi; Mariella D'Angió; Michela Deiana; Chiara Piubelli; Paola Rebora; Silvia Duranti; Paolo Bonfanti; Ilaria Capua; Sonia Tarazona; Maria Grazia Valsecchi
Journal:  Front Immunol       Date:  2022-01-27       Impact factor: 7.561

7.  Immunoreactivity of the SARS-CoV-2 entry proteins ACE-2 and TMPRSS-2 in murine models of hormonal manipulation, ageing, and cardiac injury.

Authors:  Susan Bengs; Alexia Rossi; Vera Regitz-Zagrosek; Catherine Gebhard; Martina Haberecker; Nidaa Mikail; Alexander Meisel; Ahmed Haider; Muriel Grämer; Angela Portmann; Atanas Todorov; Christof Schönenberger; Caroline E Gebhard; Gabriela M Kuster
Journal:  Sci Rep       Date:  2021-12-14       Impact factor: 4.379

Review 8.  An overview of sex hormones in relation to SARS-CoV-2 infection.

Authors:  Marzieh Saei Ghare Naz; Mojdeh Banaei; Sareh Dashti; Fahimeh Ramezani Tehrani
Journal:  Future Virol       Date:  2021-07-20       Impact factor: 1.831

9.  Modeling the Contribution of Male Testosterone Levels to the Duration of Positive COVID Testing among Hospitalized Male COVID-19 Patients.

Authors:  Stefano Salciccia; Michael L Eisenberg; Martina Maggi; Silvia Lai; Claudio Maria Mastroianni; Patrizia Pasculli; Maria Rosa Ciardi; Vittorio Canale; Matteo Ferro; Gian Maria Busetto; Ettore De Berardinis; Gian Piero Ricciuti; Alessandro Sciarra; Francesco Del Giudice
Journal:  Diagnostics (Basel)       Date:  2021-03-24

10.  COVID-19 susceptibility variants associate with blood clots, thrombophlebitis and circulatory diseases.

Authors:  Areti Papadopoulou; Hanan Musa; Mathura Sivaganesan; David McCoy; Panos Deloukas; Eirini Marouli
Journal:  PLoS One       Date:  2021-09-03       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.